# **Data Changes for the CCDD FEB Release Candidate 2021**

## **Based on the QA Release** 20210201

|  |  |
| --- | --- |
| Data entered by | J. Hutsul |
| Data checked by | B. Prime |

## **TM File**

### **Deprecation**

The following TM concept(s) needs to be added back into the TM File with a status of **deprecated**. [Reason for deprecation].

|  |  |  |
| --- | --- | --- |
| **tm\_code** | **tm \_formal\_name** | **tm\_status** |
|  | [NONE] | Deprec |

### **Code permanence – name changes**

The following TM concept(s) need to keep its/their existing tm\_code even though their formal name has changed. [Reason for name change].

|  |  |  |
| --- | --- | --- |
| **tm\_code (to keep)** | **tm \_formal\_name** | **tm\_code in QA Release was** |
|  | [NONE] |  |

### **Concept permanence - returns**

The following TM concept(s) is/are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate with a status of “inactive”, when its/their supporting NTPs and MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **tm\_code** | **tm \_formal\_name** |
|  | [NONE] |

## **NTP File**

### **Deprecation**

The following NTP concept(s) need to be added back into the NTP File with status of **deprecated**.

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
|  | [NONE] |  | Deprec |

### **Code permanence – name changes**

The following NTP concepts need to keep their existing ntp\_code even though their formal name has changed.

|  |  |  |
| --- | --- | --- |
| **ntp\_code (to keep)** | **ntp \_formal\_name** | **ntp\_code in QA Release was** |
|  | [NONE] |  |

### **Concept permanence – returns check**

The following NTP concepts are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate, when their supporting MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **ntp\_code** | **ntp \_formal\_name** |
| 9013081 | docetaxel 80 mg per 2 mL solution for injection vial with diluent solution |
| 9000017 | hydrocodone 5 mg per 5 mL and phenyltoloxamine 10 mg per 5 mL oral suspension |

## **MP File**

### **Deprecation (very rare)**

**No new deprecated concepts**

### **Deprecation – manual return**

The following MP concepts need to be added back into the MP File with status of **deprecated**. For both DINs, they have had additional UoP added. Both products now have new MP.

|  |  |  |  |
| --- | --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_fr\_description** | **mp\_status** |
| 02182971 | METHOTREXATE INJECTION USP (methotrexate (methotrexate sodium) 1000 mg per 40 mL solution for injection vial) PFIZER CANADA ULC | METHOTREXATE INJECTION USP (méthotrexate (méthotrexate sodique) 1000 mg par 40 mL solution injectable fiole) PFIZER CANADA ULC | Deprec |
| 02182777 | METHOTREXATE INJECTION USP (methotrexate (methotrexate sodium) 500 mg per 20 mL solution for injection vial) PFIZER CANADA ULC | METHOTREXATE INJECTION USP (méthotrexate (méthotrexate sodique) 500 mg par 20 mL solution injectable fiole) PFIZER CANADA ULC | Deprec |

The following MP concepts are generating as active but need to be set to **deprecated**. For both products, they have been assigned a new DIN (02474891, 02474735). This will have to be done manually each month.

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
| 77700322 | METHOTREXATE INJECTION BP (methotrexate (methotrexate sodium) 1000 mg per 40 mL solution for injection vial) ACCORD HEALTHCARE INC | Deprec |
| 77700323 | METHOTREXATE INJECTION BP (methotrexate (methotrexate sodium) 500 mg per 20 mL solution for injection vial) ACCORD HEALTHCARE INC | Deprec |

### **DPD descriptors**

The following concept(s) needs to have the DPD descriptor added to the brand name to allow differentiation between duplicate mp\_formal names.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_  code | mp\_code | mp\_formal\_name | DPD descriptor | DPD descriptor - FR |
|  | [NONE] |  |  |  |

### **Concept permanence – manual return**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_code | mp\_code | mp\_formal\_name | mp\_fr\_description | CCDD status |
|  | [NONE] |  |  |  |

### **Concept permanence – returns check**

The following MPs need to be added to the Whitelist to make sure that they (and their associated NTPs/TMs) continue to be present in the release:

|  |  |  |  |
| --- | --- | --- | --- |
| **drug\_code** | **mp\_code** | **mp\_formal\_name** | **DPD status** |
| 74075 | 02255553 | ACT ATENOLOL (atenolol 100 mg oral tablet) ACTAVIS PHARMA COMPANY | Cancelled postmarket Exp 2020.11.30 |
| 74074 | 02255545 | ACT ATENOLOL (atenolol 50 mg oral tablet) ACTAVIS PHARMA COMPANY | Cancelled postmarket Exp 2020.11.30 |
| 96751 | 02476665 | APO-HYDROMORPHONE CR (hydromorphone hydrochloride 18 mg prolonged-release oral capsule) APOTEX INC | Dormant 2021.01.11 |
| 96753 | 02476681 | APO-HYDROMORPHONE CR (hydromorphone hydrochloride 30 mg prolonged-release oral capsule) APOTEX INC | Dormant 2021.01.08 |
| 90811 | 02423383 | APO-SOLIFENACIN (solifenacin succinate 10 mg oral tablet) APOTEX INC | Dormant 2020.09.10 |
| 90810 | 02423375 | APO-SOLIFENACIN (solifenacin succinate 5 mg oral tablet) APOTEX INC | Dormant 2020.08.06 |
| 93648 | 02450356 | BIO-LEVETIRACETAM (levetiracetam 500 mg oral tablet) BIOMED PHARMA | Dormant  2021.01.01 |
| 89824 | 02413590 | CARBAMAZEPINE CR (carbamazepine 200 mg prolonged-release oral tablet) PRO DOC LIMITEE | Cancelled postmarket Exp 2021.01.31 |
| 37185 | 02218887 | HEMORRHOIDAL OINTMENT (pramoxine hydrochloride 1 % and zinc sulfate monohydrate 0.5 % rectal ointment) PHARMASCIENCE INC | Cancelled postmarket Exp 2021.01.31 |
| 73853 | 02253577 | MEDROXY-5 (medroxyprogesterone acetate 5 mg oral tablet) PRO DOC LIMITEE | Cancelled postmarket Exp 2021.01.31 |
| 89212 | 02407434 | MINT-ESCITALOPRAM (escitalopram (escitalopram oxalate) 20 mg oral tablet) MINT PHARMACEUTICALS INC | Dormant 2020.12.21 |
| 92130 | 02436981 | MINT-OLANZAPINE ODT (olanzapine 15 mg orodispersible tablet) MINT PHARMACEUTICALS INC | Dormant 2020.12.23 |
| 81185 | 02326485 | MINT-PIOGLITAZONE (pioglitazone (pioglitazone hydrochloride) 30 mg oral tablet) MINT PHARMACEUTICALS INC | Dormant 2021.01.03 |
| 81186 | 02326493 | MINT-PIOGLITAZONE (pioglitazone (pioglitazone hydrochloride) 45 mg oral tablet) MINT PHARMACEUTICALS INC | Dormant 2020.12.12 |
| 17972 | 02137534 | MYLAN-ALPRAZOLAM (alprazolam 0.25 mg oral tablet) MYLAN PHARMACEUTICALS ULC | Cancelled postmarket Exp 2021.01.31 |
| 48166 | 02229813 | MYLAN-ALPRAZOLAM (alprazolam 1 mg oral tablet) MYLAN PHARMACEUTICALS ULC | Cancelled postmarket Exp 2021.01.31 |
| 81130 | 02325950 | OXYCODONE (oxycodone hydrochloride 5 mg oral tablet) PRO DOC LIMITEE | Cancelled postmarket Exp 2021.01.31 |
| 6417 | 00607789 | RATIO-HEMCORT-HC (hydrocortisone acetate 0.5 % and zinc sulfate 0.5 % rectal ointment) TEVA CANADA LIMITED | Cancelled postmarket Exp 2021.01.31 |
| 72109 | 02247815 | RIVA-RANITIDINE 300 (ranitidine (ranitidine hydrochloride) 300 mg oral tablet) LABORATOIRE RIVA INC. | Cancelled postmarket Exp 2021.01.31 |
| 18990 | 02177080 | TAXOTERE (docetaxel 80 mg per 2 mL solution for injection vial with diluent solution) SANOFI-AVENTIS CANADA INC | Cancelled postmarket Exp. 2021.01.31 |
| 12216 | 01916971 | TUSSIONEX (hydrocodone 5 mg per 5 mL and phenyltoloxamine 10 mg per 5 mL oral suspension) SANOFI-AVENTIS CANADA INC | Cancelled postmarket Exp. 2021.01.31 |
| 67614 | 02243684 | ZYVOXAM 600 MG (linezolid 600 mg oral tablet) PFIZER CANADA ULC | Cancelled postmarket Exp. 2021.01.31 |

## **Blacklist (on GitHub)**

The following changes have been made to the Blacklist for the OCT Release Candidate. The list as it is on GitHub should be used.

Changes that have been made to the Blacklist are as follows:  
ACTION is either:

* STAY on Blacklist
* ADD to Blacklist
* REMOVE from Blacklist

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **ntp\_code** | **ntp\_formal\_name** | **drug\_code** | **mp\_code** | **mp\_formal\_name** | **ACTION** |
| 9014411 | bismuth subsalicylate 35.2 mg per mL oral suspension | 96658 | 02475855 | EXTRA STRENGTH BISMUTH (bismuth subsalicylate 35.2 mg per mL oral suspension) JUNO OTC INC | STAY |
| 9014413 | isoproterenol hydrochloride 0.2 mg per mL solution for injection | 99218 | 02502615 | ISOPROTERENOL HYDROCHLORIDE INJECTION USP (isoproterenol hydrochloride 0.2 mg per mL solution for injection) MARCAN PHARMACEUTICALS INC | STAY |
| 3e5178c5620bdeb251e1a3e501d66ea6 | galcanezumab 100 mg per mL solution for injection | 99448 | 2505134 | EMGALITY (galcanezumab 100 mg per mL solution for injection) ELI LILLY CANADA INC | ADD |
| 6e51225740fa2c016da765a751cd85b0 | benralizumab 30 mg per mL solution for injection | 98601 | 2496135 | FASENRA PEN (benralizumab 30 mg per mL solution for injection) ASTRAZENECA CANADA INC | ADD |
| 909e47015e88b527bd2767f9c217ac55 | filgrastim (pegfilgrastim) 6 mg per 0.6 mL solution for injection | 99556 | 2506238 | NYVEPRIA (filgrastim (pegfilgrastim) 6 mg per 0.6 mL solution for injection) PFIZER CANADA ULC | ADD |
| fddecce04f3954d057eea955708ec5fd | lanadelumab 300 mg per 2 mL solution for injection | 99498 | 2505614 | TAKHZYRO (lanadelumab 300 mg per 2 mL solution for injection) SHIRE PHARMA CANADA ULC | ADD |
| ee56fddff53880c3177c4b4c021bd60e | arsenic trioxide 12 mg per 6 mL solution for injection | 97091 | 2480387 | TRISENOX (arsenic trioxide 12 mg per 6 mL solution for injection) TEVA CANADA LIMITED | ADD |
| 7fd66abcf6f0f23ba5a609f5a07d20b2 | amikacin (amikacin sulfate) 500 mg per 2 mL solution for injection | 99595 | 2506599 | VPI-AMIKACIN (amikacin (amikacin sulfate) 500 mg per 2 mL solution for injection) VPI PHARMACEUTICALS INC | ADD |